Press release
Dermatomyositis Pipeline 2025 Report by DelveInsight: A Deep Dive into the Competitive Landscape, Investigational Therapies, Clinical Progress, and Transformative Opportunities in Treatment
Curious about the latest updates in the Dermatomyositis Pipeline? Click here to explore the therapies and trials making headlines @ Dermatomyositis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Dermatomyositis Pipeline Report
* On 15 September 2025, Cabaletta Bio announced a study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
* On 11 September 2025, AstraZeneca conducted a study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) [polymyositis (PM) or dermatomyositis (DM)] while receiving standard of care (SoC) treatment.
* DelveInsight's Dermatomyositis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Dermatomyositis treatment.
* The leading Dermatomyositis Companies such as Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
* Promising Dermatomyositis Therapies such as Brepocitinib, Lenabasum 20 mg, GLPG3667, Octagam 10%, Tocilizumab, PN-101, KZR-616 and others.
Want to know which companies are leading innovation in Dermatomyositis? Dive into the full pipeline insights @ Dermatomyositis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Dermatomyositis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Dermatomyositis Pipeline Report also highlights the unmet needs with respect to the Dermatomyositis.
Dermatomyositis Overview
Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by muscle weakness and distinctive skin manifestations. This idiopathic inflammatory myopathy primarily affects the proximal muscles, including the hips, thighs, shoulders, and neck, leading to progressive and symmetrical weakness that can significantly impair daily activities. Skin symptoms include Gottron's papules, which are raised, scaly bumps on the knuckles, elbows, and knees, and a heliotrope rash, characterized by a purplish discoloration and swelling around the eyes. Other notable rashes include the V-sign and shawl sign, which appear over the chest and shoulders respectively, as well as mechanic's hands, which feature rough, cracked skin on the sides of the fingers.
Dermatomyositis Emerging Drugs Profile
* EFG PH20: argenx
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. A Phase II/III study (NCT05523167) is evaluating the efficacy and safety of efgartigimod PH20 SC compared to placebo in adults with active IIMs, including DM, immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), and antisynthetase syndrome. The primary endpoint is treatment response measured by Total Improvement Score (TIS). Another study (NCT05979441) is assessing the long-term safety and efficacy of subcutaneous efgartigimod in adults with IIMs. The drug is currently in Phase III stage of development to treat Dermatomyositis.
* KZR-616: Kezar Life Sciences
KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body's immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.
If you're tracking ongoing Dermatomyositis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Dermatomyositis Treatment Drugs [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dermatomyositis Companies
Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
Dermatomyositis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Dermatomyositis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Dermatomyositis Pipeline Report covers it all - check it out now @ Dermatomyositis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Dermatomyositis Pipeline Report
* Coverage- Global
* Dermatomyositis Companies- Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
* Dermatomyositis Therapies- Brepocitinib, Lenabasum 20 mg, GLPG3667, Octagam 10%, Tocilizumab, PN-101, KZR-616 and others.
* Dermatomyositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Dermatomyositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Dermatomyositis Treatment landscape in this detailed analysis @ Dermatomyositis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Dermatomyositis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dermatomyositis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* EFG PH20: argenx
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KZR-616: Kezar Life Sciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Dermatomyositis Key Companies
* Dermatomyositis Key Products
* Dermatomyositis- Unmet Needs
* Dermatomyositis- Market Drivers and Barriers
* Dermatomyositis- Future Perspectives and Conclusion
* Dermatomyositis Analyst Views
* Dermatomyositis Key Companies
* 24. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dermatomyositis-pipeline-2025-report-by-delveinsight-a-deep-dive-into-the-competitive-landscape-investigational-therapies-clinical-progress-and-transformative-opportunities-in-treatment]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatomyositis Pipeline 2025 Report by DelveInsight: A Deep Dive into the Competitive Landscape, Investigational Therapies, Clinical Progress, and Transformative Opportunities in Treatment here
News-ID: 4190580 • Views: …
More Releases from ABNewswire
Multifocal Motor Neuropathy Pipeline Drugs Report 2025: An Analytical Outlook Co …
DelveInsight's, "Multifocal Motor Neuropathy Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape. It covers the Multifocal Motor Neuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multifocal Motor Neuropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about…
Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R …
DelveInsight's "Osteosarcoma Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Othe steosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Osteosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Osteosarcoma Pipeline?…
Select Motorz Offers Expert Tips for Thorough Used Car Inspections
Image: https://www.abnewswire.com/upload/2025/09/6c9da227845e2ee9cdcac2979cfc9b7d.jpg
Hesperia, CA - September 19, 2025 - Select Motorz provides valuable advice to market customers seeking a used car and intends to guide them to make wise and confident choices. Having the professional advice on what to be aware of when there is an inspection, Select Motorz ensures that the buyers can make the right choice and buy the car that fits their needs and financial possibilities.
How Select Motorz…
Understanding Key Features of Used GMC Trucks with Dallas Lease Return
Dallas, TX - September 19, 2025 - Dallas Lease Returns is providing professional advice on what to look for when buying a used GMC truck that will lead to satisfaction. GMC trucks are of great value as they are known to be durable, technological, and performing. Learning about major characteristics, buyers are able to make the right choice and locate a truck that would suit them.
Top features to look for…
More Releases for Dermatomyositis
Dermatomyositis market expected to reach USD 1.2 billion by 2034
Dermatomyositis is a rare, chronic autoimmune condition characterized by muscle inflammation and distinctive skin rashes. The disease impacts both adults and children, with complications that include interstitial lung disease and increased cancer risk. Despite its rarity, dermatomyositis places a significant burden on patients due to disability, reduced quality of life, and high treatment costs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71381
In recent years, the dermatomyositis market has seen…
Dermatomyositis Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Dermatomyositis…
Dermatomyositis (DM) Market Emerging Trends and Growth Prospects 2034
Introduction
Dermatomyositis (DM) is a rare, chronic autoimmune inflammatory myopathy characterized by muscle weakness and distinctive skin rashes. It affects both adults and children and is associated with complications such as interstitial lung disease, malignancies, and cardiovascular involvement. The disease significantly reduces patient quality of life and requires long-term medical care.
Historically treated with corticosteroids and immunosuppressants, the market is now evolving with biologics, monoclonal antibodies, and targeted immunotherapies. Increasing global awareness…
Dermatomyositis Treatment Market Growth Accelerates: Strategic Forecast Predicts …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Dermatomyositis Treatment Industry Market Size Be by 2025?
The market for dermatomyositis treatment has seen significant expansion in the past few years. It is projected to escalate from $0.85 billion in 2024 to $0.91 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%.…
Dermatomyositis Market - Defying the challenges of dermatomyositis: choose our t …
Newark, New Castle, USA: The "Dermatomyositis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dermatomyositis Market: https://www.growthplusreports.com/report/dermatomyositis-market/8675
This latest report researches the industry structure, sales, revenue, price and…
Dermatomyositis Market Size, Analysis, Share, Research, Business Growth and Fore …
Dermatomyositis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dermatomyositis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview of the…
